Tue, July 27, 2010
Mon, July 26, 2010
Fri, July 23, 2010
Thu, July 22, 2010
Wed, July 21, 2010
Tue, July 20, 2010
[ Tue, Jul 20th 2010 ] - Market Wire
00 AM EDT
Mon, July 19, 2010
Sun, July 18, 2010
Sat, July 17, 2010
Fri, July 16, 2010
Thu, July 15, 2010
Wed, July 14, 2010
Tue, July 13, 2010
Mon, July 12, 2010
Fri, July 9, 2010
Thu, July 8, 2010
Wed, July 7, 2010
Tue, July 6, 2010
Mon, July 5, 2010
Fri, July 2, 2010

SurModics to Webcast Third Quarter Fiscal Year 2010 Earnings Conference Call July 28


//health-fitness.news-articles.net/content/2010/ .. -year-2010-earnings-conference-call-july-28.html
Published in Health and Fitness on Wednesday, July 14th 2010 at 13:15 GMT by Market Wire   Print publication without navigation


EDEN PRAIRIE, Minn.--([ BUSINESS WIRE ])--SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery and surface modification technologies to the healthcare industry, announced today that it will host a live webcast of its third quarter 2010 conference call on Wednesday, July 28, at 4:00 p.m. CT. The Company will issue an earnings news release after the market closes that afternoon.

Phil Ankeny, interim chief executive officer, senior vice president and chief financial officer, will recap the third quarter 2010 financial results and accomplishments. To access the webcast, go to the investor relations portion of the Companya™s website at [ www.surmodics.com ] the day of the conference call and click on the webcast icon.

An audio replay will be available beginning at 7:00 p.m. CT on Wednesday, July 28, until 7:00 p.m. CT on Wednesday, August 4 and can be accessed by dialing 800-406-7325 and entering conference call ID passcode 4330268. In addition, the conference call audio will be archived on the Companya™s website following the call.

About SurModics, Inc.

SurModicsa™ vision is to extend and improve the lives of patients through technology innovation. The Company partners with the worlda™s foremost medical device, pharmaceutical and life science companies to develop and commercialize innovative products that result in improved diagnosis and treatment for patients. Core offerings include: drug delivery technologies (coatings, microparticles, nanoparticles, and implants); surface modification coating technologies that impart lubricity, prohealing, and biocompatibility capabilities; and components for in vitro diagnostic test kits and specialized surfaces for cell culture and microarrays. SurModics is headquartered in Eden Prairie, Minnesota and its SurModics Pharmaceuticals subsidiary is located in Birmingham, Alabama. For more information about the Company, visit [ www.surmodics.com ]. The content of SurModicsa™ website is not part of this release or part of any filings the Company makes with the SEC.


Publication Contributing Sources